The stock of NeuroPace Inc (NASDAQ: NPCE) has decreased by -8.58 when compared to last closing price of 12.94. Despite this, the company has experienced a -10.17% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-11 that NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. (“NeuroPace, Inc.”) (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, “announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Is It Worth Investing in NeuroPace Inc (NASDAQ: NPCE) Right Now?
Company’s 36-month beta value is 2.03.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NPCE is 22.82M, and currently, short sellers hold a 1.56% ratio of that floaft. The average trading volume of NPCE on June 12, 2025 was 283.44K shares.
NPCE’s Market Performance
The stock of NeuroPace Inc (NPCE) has seen a -10.17% decrease in the past week, with a -11.52% drop in the past month, and a 7.84% gain in the past quarter. The volatility ratio for the week is 4.12%, and the volatility levels for the past 30 days are at 9.54% for NPCE. The simple moving average for the last 20 days is -19.57% for NPCE stock, with a simple moving average of 10.45% for the last 200 days.
Analysts’ Opinion of NPCE
Many brokerage firms have already submitted their reports for NPCE stocks, with H.C. Wainwright repeating the rating for NPCE by listing it as a “Buy.” The predicted price for NPCE in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on May 28, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see NPCE reach a price target of $17. The rating they have provided for NPCE stocks is “Buy” according to the report published on January 21st, 2025.
Wells Fargo gave a rating of “Overweight” to NPCE, setting the target price at $20 in the report published on March 14th of the previous year.
NPCE Trading at -8.35% from the 50-Day Moving Average
After a stumble in the market that brought NPCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.65% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at NPCE starting from ORBIMED ADVISORS LLC, who sale 168,136 shares at the price of $15.85 back on May 14 ’25. After this action, ORBIMED ADVISORS LLC now owns 3,238,199 shares of NeuroPace Inc, valued at $2,665,333 using the latest closing price.
Morrell Martha, the CHIEF MEDICAL OFFICER of NeuroPace Inc, sale 78,334 shares at $13.72 during a trade that took place back on Feb 21 ’25, which means that Morrell Martha is holding 81,993 shares at $1,074,844 based on the most recent closing price.
Stock Fundamentals for NPCE
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.75 for the gross margin
The net margin for NeuroPace Inc stands at -0.22. The total capital return value is set at -0.2. Equity return is now at value -128.49, with -23.73 for asset returns.
Based on NeuroPace Inc (NPCE), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 3.01. The interest coverage ratio of the stock is -4.39.
Currently, EBITDA for the company is -16.57 million with net debt to EBITDA at -2.98. When we switch over and look at the enterprise to sales, we see a ratio of 5.15. The receivables turnover for the company is 5.46for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.63.
Conclusion
In a nutshell, NeuroPace Inc (NPCE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
